Von Willebrand factor for outcome prediction within different clinical stages of advanced chronic liver disease.
Journal
Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234
Informations de publication
Date de publication:
14 Mar 2024
14 Mar 2024
Historique:
revised:
28
11
2023
received:
09
11
2023
accepted:
29
02
2024
medline:
14
3
2024
pubmed:
14
3
2024
entrez:
14
3
2024
Statut:
aheadofprint
Résumé
The prognostic performance of von Willebrand factor (VWF) may vary across clinical stages of advanced chronic liver disease (ACLD). Therefore, we investigated the evolution of VWF and other biomarkers throughout the full ACLD spectrum and evaluated their stage-specific prognostic utility. We retrospectively included Viennese ACLD patients with available information on hepatic venous pressure gradient (HVPG), C-reactive protein (CRP)/VWF levels and outcomes. ACLD stages were defined according to D'Amico et al. We included an external validation cohort from Padua. We observed gradual increases in VWF throughout ACLD stages. In contrast, HVPG levelled off in decompensated ACLD (dACLD), whereas MELD showed only minor changes in the early stages and CRP did not increase until stage 3. VWF was associated with hepatic decompensation/liver-related death in compensated ACLD (cACLD) in a fully adjusted model, while it was not independently predictive of ACLF/liver-related death in dACLD. After backward selection, HVPG/CRP/VWF remained the main predictors of hepatic decompensation/liver-related death in cACLD. Notably, the performance of the non-invasive CRP/VWF-based model was comparable to invasive HVPG-based models (C-index:0.765 ± 0.034 vs. 0.756 ± 0.040). The discriminative ability of the CRP/VWF-based model was confirmed in an external validation cohort using another VWF assay which yielded systematically lower values. VWF is the only biomarker that gradually increases across all ACLD stages. It is of particular prognostic value in cACLD, where a CRP/VWF-based model is equivalent to an invasive HVPG-based model. Systematic differences in VWF underline the importance of interlaboratory surveys. Moreover, our findings reinforce the notion that, already in cACLD, inflammation is a key disease-driving mechanism.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
The prognostic performance of von Willebrand factor (VWF) may vary across clinical stages of advanced chronic liver disease (ACLD). Therefore, we investigated the evolution of VWF and other biomarkers throughout the full ACLD spectrum and evaluated their stage-specific prognostic utility.
METHODS
METHODS
We retrospectively included Viennese ACLD patients with available information on hepatic venous pressure gradient (HVPG), C-reactive protein (CRP)/VWF levels and outcomes. ACLD stages were defined according to D'Amico et al. We included an external validation cohort from Padua.
RESULTS
RESULTS
We observed gradual increases in VWF throughout ACLD stages. In contrast, HVPG levelled off in decompensated ACLD (dACLD), whereas MELD showed only minor changes in the early stages and CRP did not increase until stage 3. VWF was associated with hepatic decompensation/liver-related death in compensated ACLD (cACLD) in a fully adjusted model, while it was not independently predictive of ACLF/liver-related death in dACLD. After backward selection, HVPG/CRP/VWF remained the main predictors of hepatic decompensation/liver-related death in cACLD. Notably, the performance of the non-invasive CRP/VWF-based model was comparable to invasive HVPG-based models (C-index:0.765 ± 0.034 vs. 0.756 ± 0.040). The discriminative ability of the CRP/VWF-based model was confirmed in an external validation cohort using another VWF assay which yielded systematically lower values.
CONCLUSION
CONCLUSIONS
VWF is the only biomarker that gradually increases across all ACLD stages. It is of particular prognostic value in cACLD, where a CRP/VWF-based model is equivalent to an invasive HVPG-based model. Systematic differences in VWF underline the importance of interlaboratory surveys. Moreover, our findings reinforce the notion that, already in cACLD, inflammation is a key disease-driving mechanism.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
Références
Mandorfer M, Hernández-Gea V, García-Pagán JC, Reiberger T. Noninvasive diagnostics for portal hypertension: a comprehensive review. Semin Liver Dis. 2020;40(3):240-255.
La Mura V, Reverter JC, Flores-Arroyo A, Raffa S, Reverter E, Seijo S, et al. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. Gut. 2011;60(8):1133-1138.
Simbrunner B, Caparrós E, Neuwirth T, Schwabl P, Königshofer P, Bauer D, et al. Bacterial translocation occurs early in cirrhosis and triggers a selective inflammatory response. Hepatol Int. 2023;17(4):1045-1056.
Mandorfer M, Schwabl P, Paternostro R, Pomej K, Bauer D, Thaler J, et al. Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity. Aliment Pharmacol Ther. 2018;47(7):980-988.
Starlinger P, Ahn JC, Mullan A, Gyoeri GP, Pereyra D, Alva-Ruiz R, et al. The addition of C-reactive protein and von Willebrand factor to model for end-stage liver disease-sodium improves prediction of waitlist mortality. Hepatology. 2021;74(3):1533-1545.
Enomoto M, Takaya H, Namisaki T, Fujinaga Y, Nishimura N, Sawada Y, et al. Ratio of von Willebrand factor antigen to ADAMTS13 activity is a useful biomarker for acute-on-chronic liver failure development and prognosis in patients with liver cirrhosis. Hepatol Res. 2022;52(4):390-400.
Ferlitsch M, Reiberger T, Hoke M, Salzl P, Schwengerer B, Ulbrich G, et al. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. Hepatology. 2012;56(4):1439-1447.
Jachs M, Hartl L, Simbrunner B, Bauer D, Paternostro R, Scheiner B, et al. The sequential application of Baveno VII criteria and VITRO score improves diagnosis of clinically significant portal hypertension. Clin Gastroenterol Hepatol. 2023;21(7):1854-1863.e10.
Pomej K, Scheiner B, Balcar L, Nussbaumer RJ, Weinzierl J, Paternostro R, et al. Clinical significance of substantially elevated von Willebrand factor antigen levels in patients with advanced chronic liver disease. Dig Liver Dis. 2022;54(10):1376-1384.
Simbrunner B, Villesen IF, Scheiner B, Paternostro R, Schwabl P, Stättermayer AF, et al. Von Willebrand factor processing in patients with advanced chronic liver disease and its relation to portal hypertension and clinical outcome. Hepatol Int. 2023;17:1532-1544.
Jachs M, Hartl L, Simbrunner B, Bauer D, Paternostro R, Scheiner B, et al. Decreasing von Willebrand factor levels upon nonselective Beta blocker therapy indicate a decreased risk of further decompensation, acute-on-chronic liver failure, and death. Clin Gastroenterol Hepatol. 2022;20(6):1362-1373.e6.
D'Amico G, Morabito A, D'Amico M, Pasta L, Malizia G, Rebora P, et al. Clinical states of cirrhosis and competing risks. J Hepatol. 2018;68(3):563-576.
Reiberger T, Schwabl P, Trauner M, Peck-Radosavljevic M, Mandorfer M. Measurement of the hepatic venous pressure gradient and Transjugular liver biopsy. J Vis Exp. 2020;(160):e58819.
van Buuren S, Groothuis-Oudshoorn K. Mice: multivariate imputation by chained equations in R. J Stat Softw. 2011;45(3):1-67.
Heinze G, Dunkler D. Five myths about variable selection. Transpl Int. 2017;30(1):6-10.
Györi GP, Pereyra D, Rumpf B, Hackl H, Köditz C, Ortmayr G, et al. The von Willebrand factor facilitates model for end-stage liver disease-independent risk stratification on the waiting list for liver transplantation. Hepatology. 2020;72(2):584-594.
Paton A, Reynolds TB, Sherlock S. Assessment of portal venous hypertension by catheterisation of hepatic vein. Lancet. 1953;1(6767):918-921.
Reiberger T. The value of liver and spleen stiffness for evaluation of portal hypertension in compensated cirrhosis. Hepatol Commun. 2022;6(5):950-964.
Albornoz L, Alvarez D, Otaso JC, Gadano A, Salviú J, Gerona S, et al. Von Willebrand factor could be an index of endothelial dysfunction in patients with cirrhosis: relationship to degree of liver failure and nitric oxide levels. J Hepatol. 1999;30(3):451-455.
Zanetto A, Campello E, Bulato C, Burra P, Senzolo M, Simioni P. von Willebrand factor in hospitalized patients with acute decompensation of cirrhosis is increased but not associated with development of ACLF. Dig Liver Dis. 2023;55(1):139-141.
Reuken PA, Kussmann A, Kiehntopf M, Budde U, Stallmach A, Claus RA, et al. Imbalance of von Willebrand factor and its cleaving protease ADAMTS13 during systemic inflammation superimposed on advanced cirrhosis. Liver Int. 2015;35(1):37-45.
Zanetto A, Campello E, Bulato C, Gavasso S, Saggiorato G, Shalaby S, et al. Global hemostatic profiling in patients with decompensated cirrhosis and bacterial infections. JHEP Rep. 2022;4(7):100493.
Kalambokis GN, Oikonomou A, Christou L, Kolaitis NI, Tsianos EV, Christodoulou D, et al. von Willebrand factor and procoagulant imbalance predict outcome in patients with cirrhosis and thrombocytopenia. J Hepatol. 2016;65(5):921-928.
Sacco M, Tardugno M, Lancellotti S, Ferretti A, Ponziani FR, Riccardi L, et al. ADAMTS-13/von Willebrand factor ratio: a prognostic biomarker for portal vein thrombosis in compensated cirrhosis. A prospective observational study. Dig Liver Dis. 2022;54(12):1672-1680.
Costa D, Simbrunner B, Jachs M, Hartl L, Bauer D, Paternostro R, et al. Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality. J Hepatol. 2021;74(4):819-828.